BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35467263)

  • 1. Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9.
    Nava-Salazar S; Flores-Pliego A; Pérez-Martínez G; Parra-Hernández S; Vanoye-Carlo A; Ibarguengoitia-Ochoa F; Perichart-Perera O; Reyes-Muñoz E; Solis-Paredes JM; Espino Y Sosa S; Estrada-Gutierrez G
    Reprod Sci; 2022 Nov; 29(11):3242-3253. PubMed ID: 35467263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
    Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
    J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2.
    Chae HS; Pel P; Cho J; Kim YM; An CY; Huh J; Choi YH; Kim J; Chin YW
    J Ethnopharmacol; 2021 Oct; 278():114265. PubMed ID: 34111537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of proprotein convertase subtillisin/kexin type 9 in placental salvage and lipid metabolism in women with preeclampsia.
    Vaught AJ; Boyer T; Ziogos E; Amat-Codina N; Minhas A; Darwin K; Debrosse A; Fedarko N; Burd I; Baschat A; Sharma G; Hays AG; Zakaria S; Leucker TM
    Placenta; 2023 Feb; 132():1-6. PubMed ID: 36603351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression.
    Wang J; Wang YS; Huang YP; Jiang CH; Gao M; Zheng X; Yin ZQ; Zhang J
    Phytomedicine; 2021 Oct; 91():153688. PubMed ID: 34380071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.
    Melone M; Wilsie L; Palyha O; Strack A; Rashid S
    J Am Coll Cardiol; 2012 May; 59(19):1697-705. PubMed ID: 22554600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
    Pedro-Botet J; Badimón L
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides.
    Bordicchia M; Spannella F; Ferretti G; Bacchetti T; Vignini A; Di Pentima C; Mazzanti L; Sarzani R
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30634533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogen sulfide accumulates LDL receptor precursor via downregulating PCSK9 in HepG2 cells.
    Huang Y; Ning K; Li WW; Lin G; Hou CL; Wang MJ; Zhu YC
    Am J Physiol Cell Physiol; 2020 Dec; 319(6):C1082-C1096. PubMed ID: 32938225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
    Huang M; Zhao Z; Cao Q; You X; Wei S; Zhao J; Bai M; Chen Y
    Metabolism; 2019 May; 94():88-95. PubMed ID: 30831144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Black Raspberry Extract Enhances LDL Uptake in HepG2 Cells by Suppressing PCSK9 Expression to Upregulate LDLR Expression.
    Song KH; Kim YH; Im AR; Kim YH
    J Med Food; 2018 Jun; 21(6):560-567. PubMed ID: 29569973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
    Galvan AM; Chorba JS
    J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C).
    Ben-Naim L; Khalaila I; Papo N
    Protein Eng Des Sel; 2022 Feb; 35():. PubMed ID: 35174858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin.
    Susan-Resiga D; Girard E; Essalmani R; Roubtsova A; Marcinkiewicz J; Derbali RM; Evagelidis A; Byun JH; Lebeau PF; Austin RC; Seidah NG
    J Biol Chem; 2021 Oct; 297(4):101177. PubMed ID: 34508778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
    Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.